Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial-Reference-Cited by-同舟云学术

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

Published:2020-12 Issue:12 Volume:8 Page:949-959
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

McGuire Darren K,Zinman Bernard,Inzucchi Silvio E,Wanner Christoph,Fitchett David,Anker Stefan D,Pocock Stuart,Kaspers Stefan,George Jyothis T,von Eynatten Maximilian,Johansen Odd Erik,Jamal Waheed,Mattheus Michaela,Elsasser Ulrich,Hantel Stefan,Lund Søren S

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference32 articles.

1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

2. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial;Fitchett;Eur Heart J,2016

3. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;N Engl J Med,2016

4. Comparison of time-to-first event and recurrent-event methods in randomized clinical trials;Claggett;Circulation,2018

5. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction;Solomon;N Engl J Med,2019

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial;Cardiovascular Diabetology;2024-07-11

2. Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant‐level pooled analysis from the CANVAS Program and CREDENCE trial;European Journal of Heart Failure;2024-06-26

3. Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial;Diabetes Research and Clinical Practice;2024-06

4. SGLT2i Alleviates Atherosclerosis by Inhibiting NHE1 Activation to Protect against Macrophage Senescence Induced by Angiotensin II;Combinatorial Chemistry & High Throughput Screening;2024-05-27

5. Therapy of Type 2 Diabetes;Experimental and Clinical Endocrinology & Diabetes;2024-04-10